Synta Pharmaceuticals Corp.'s STA-9090 (ganetespib) is positioned within the competitive landscape of targeted therapies for advanced non-small cell lung cancer (NSCLC). Given the high unmet need in Stage IIIB and IV NSCLC, the asset could capture significant market share if efficacy and safety are demonstrated. The completion of this Phase 2 trial suggests readiness for potential partnership or acquisition discussions, particularly with larger oncology-focused pharmaceutical companies. The market for NSCLC therapies is robust, with increasing demand for novel agents that can improve patient outcomes and extend survival. Competitive analysis indicates that while there are several existing therapies, the unique mechanism of HSP90 inhibition may provide a differentiated profile, particularly in resistant cases.